TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00934999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic mid-urethral sling (TVT)
Description: Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
Study: NCT03866616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Builders Parenting Class
Description: Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (Usual care)
Description: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics.
Study: NCT02383979

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (Comparator) Plasma Ball
Description: will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror
Description: will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
Study: NCT03752281

Intervention type: OTHER
Intervention: Investigation of health and activity
Description: During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
Study: NCT02382913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TdaP booster
Description: Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed TdaP booster (Boostrix®)
Description: Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination.
Study: NCT03623308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber cereal
Description: Whole grain and bran cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber cereal
Description: Whole grain and bran cereal
Study: NCT00665392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m², day 1. 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m² Day 1. 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 750 mg/m² day 1 to day 5. 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
Study: NCT02066857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cast made of generic plaster or fiberglass cast material
Description: Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
Study: NCT01738087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEXThaler 100/6 mcg DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEXThaler 100/6 mcg DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide Accuhaler 500 mcg
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEXThaler 200/6 mcg DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEXThaler 200/6 mcg DPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NEXThaler placebo
Description: Placebo comparator
Study: NCT04136249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Over physical activity
Description: 105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
Study: NCT04707287

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention used. This is observational study
Study: NCT04478799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutanous Posterior Tibial Nerve Stimulation
Description: children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutanous Posterior Tibial Nerve Stimulation
Description: Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
Study: NCT04245423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care for Opioid Use Disorders and Mental Health Conditions
Description: CC is delivered using the investigators' Foundations for Integrated Care model. The first line pharmacotherapy is buprenorphine-naloxone. The second line pharmacotherapy included is extended-release injectable naltrexone. Pharmacotherapy is accompanied by brief problem-solving therapy, cognitive-behavioral therapy, and/or motivational interviewing. The primary care physician, in consultation with the addictions psychiatrist and care manager, also will provide psychotropic medications for psychiatric disorders. In-person and telephone visits consist of the care manager carrying out intervention activities over 6 months. Visits are at baseline (90-minute intake appointment), home or office induction when in moderate opiate withdrawal if buprenorphine is prescribed, twice a week for two weeks with telephone calls in between visits, then weekly, and when stable once a month. There will be a final visit at 6 months. The intervention includes routine collection of urine drug screens.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Usual Care
Description: If not already waivered, PCPs will be trained and waivered to treat OUD with medications. All practices will have mental health clinicians to treat mild psychiatric disorders. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
Description: This intervention includes the Collaborative Care Intervention plus Certified Recovery Specialist to assist with treatment engagement and retention.
Study: NCT04469517

Intervention type: OTHER
Intervention: hypoxic induced factors
Description: hypoxic induced factors analyzed in blood sample

Intervention type: OTHER
Intervention: hypoxic induced factors
Description: hypoxic induced factors analyzed in blood sample
Study: NCT02085590

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously
Study: NCT03816839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant (SAR439859)
Description: Pharmaceutical form: Capsules~Route of administration: Oral
Study: NCT02038803

Intervention type: DRUG
Intervention: TOBIpodhaler
Study: NCT02066857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Generic off the shelf removable splint
Description: Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture.
Study: NCT01160965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine
Description: 15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
Study: NCT00495612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
Study: NCT03974997

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Determination of the circulating serum concentration of cytoquine TWEAK
Description: Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
Study: NCT02766764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone
Description: Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
Study: NCT04546360

Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.
Description: Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
Study: NCT01160965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% Ropivacaine
Description: 15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
Study: NCT03448367

Intervention type: DEVICE
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
Study: NCT04518124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
Study: NCT03511521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH Insulin
Description: Intermediate acting insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine
Description: basal insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine
Description: basal insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: prandial insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: prandial insulin
Study: NCT01575561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20-80 mg taken orally once daily
Study: NCT00439400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02112786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator
Description: This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator
Description: This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
Study: NCT00440271

Intervention type: DRUG
Group type: OTHER
Intervention: tipranavir

Intervention type: DRUG
Group type: OTHER
Intervention: tipranavir

Intervention type: DRUG
Group type: OTHER
Intervention: ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: Optimized Background Regimen (OBR)
Description: Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.

Intervention type: DRUG
Group type: OTHER
Intervention: Optimized Background Regimen (OBR)
Description: Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
Study: NCT02978144

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT-CT

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT-CT

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT-CT

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT-CT

Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc

Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc

Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc

Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc
Study: NCT04016168

Intervention type: BIOLOGICAL
Intervention: Blood sample collection
Description: Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
Study: NCT00685815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: 500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250cc NS IV over one hour, once on Day 3, once on Day 4
Study: NCT02698501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929
Description: MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 doses in total, 4-week intervals), administered intravenously
Study: NCT00824590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: a single oral dose of 20 mg Dimebon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: a single oral dose of 20 mg Dimebon
Study: NCT01329497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systemic dietary instruction
Description: systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
Study: NCT04028063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.
Study: NCT04007406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexfadrostat phosphate
Description: DP13 systemic administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexfadrostat phosphate
Description: DP13 systemic administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexfadrostat phosphate
Description: DP13 systemic administration
Study: NCT03745326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-KRAS G12D mTCR PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-KRAS G12D mTCR PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
Study: NCT00880412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EHT 0202 etazolate
Description: In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EHT 0202 etazolate
Description: In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
Study: NCT02862236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum extract
Description: 250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum extract
Description: 250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
Study: NCT02259010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution